This document is a publication of a European patent application (EP4499600A1) detailing a specific process for preparing Belumosudil Mesylate and its crystalline form. The application was filed by Alivus Life Sciences Limited and includes inventors from their research team. The publication date is March 18, 2026.

This patent publication does not impose direct compliance obligations on regulated entities. However, it is relevant for pharmaceutical companies and drug manufacturers involved in the development or manufacturing of Belumosudil, as it may affect intellectual property rights and market exclusivity. Compliance officers should note this publication for potential impact on R&D strategies and freedom-to-operate analyses.